Gapping up
In reaction to strong earnings/guidance:
- CLNE +15%, CARA +10.8%, LXRX +5.7%, DQ +5.4%, QHC +5%, GH +3.4%, TISI +2.9%, SENS +2.6%, NTRA +2.5%, CHU +2.2%, SLDB +2%, BTG +0.8%, EVOP +0.5%
Other news:
- AERI +8.8% (receives FDA approval for Rocklatan; issues FY19 guidance)
- ACB +7.7% (appointed Nelson Peltz as a Strategic Advisor)
- EYPT +5.1% (announces U.S. commercial launch of DEXYCU 9%)
- WLL +5% (to join S&P SmallCap 600)
- PCG +1.8% (will not face criminal charges for 2017 wildfires)
- HBI +0.9% (approves appointment of Ronald L. Nelson as Chairman of the Board)
- LDOS +0.7% (U.S. Navy awards Leidos contract to support aircraft readiness worldwide; total potential value of $12.6 billion)
Analyst comments:
- CCL +1.9% (upgraded to Buy from Neutral at Goldman), SAN +1.9% (upgraded to Outperform at RBC Capital Mkts)
- MOMO +1.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ESPR +1% (upgraded to Neutral from Underweight at JP Morgan)
- CVS +1% (initiated with Outperform at Bernstein)
